Free Trial
NASDAQ:VERV

Verve Therapeutics Q4 2024 Earnings Report

Verve Therapeutics logo
$4.24 -0.05 (-1.19%)
Closing price 03:59 PM Eastern
Extended Trading
$4.28 +0.05 (+1.09%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verve Therapeutics EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.72
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Verve Therapeutics Revenue Results

Actual Revenue
$13.08 million
Expected Revenue
$3.94 million
Beat/Miss
Beat by +$9.15 million
YoY Revenue Growth
N/A

Verve Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Verve Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025

Verve Therapeutics Earnings Headlines

Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
FY2025 EPS Estimate for Verve Therapeutics Lifted by Analyst
Research Analysts Offer Predictions for VERV FY2026 Earnings
See More Verve Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verve Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verve Therapeutics and other key companies, straight to your email.

About Verve Therapeutics

Verve Therapeutics (NASDAQ:VERV), a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

View Verve Therapeutics Profile

More Earnings Resources from MarketBeat